Our proposed adaptation enabled SuStaIn to be applied to a multimodal set of biomarkers, uncovering five subtypes: ‘Typical AD Early Tau’, ‘Typical AD Late Tau’, ‘Cortical’, ‘Cognitive’ and ‘Subcortical’, in order of prevalence. Here, MAPT is linked to Alzheimer disease.